Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Boldt v. Boldt: A Pediatric Ethics Perspective

Autor: Douglas S. Diekema

Publikováno v: The Journal of Clinical Ethics. 20:251-257

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4a78c0cbe83399a8c3180e9faa619434
https://doi.org/10.1086/jce200920309

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy.

Autor: Gross S; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Ihlow J; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany. jana.ihlow@charite.de.; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany. jana.ihlow@charite.de.; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Academy, BIH Charité Clinician Scientist Program, Charitéplatz 1, 10117, Berlin, Germany. jana.ihlow@charite.de., Busack L; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Adamiak K; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Schrezenmeier J; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Academy, BIH Charité Clinician Scientist Program, Charitéplatz 1, 10117, Berlin, Germany., Jesse J; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Schwarz M; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Flörcken A; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Vuong LG; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Rieger K; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Krönke J; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, German Cancer Consortium (DKTK), partner site, Berlin, Germany., le Coutre P; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., Boldt V; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., von Brünneck AC; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Horst D; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Burmeister T; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., Blau IW; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany., Keller U; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, German Cancer Consortium (DKTK), partner site, Berlin, Germany., Bullinger L; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, German Cancer Consortium (DKTK), partner site, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., Westermann J; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Campus Charité-Mitte and Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany. joerg.westermann@charite.de.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany. joerg.westermann@charite.de.

Publikováno v: Blood cancer journal [Blood Cancer J] 2024 Sep 16; Vol. 14 (1), pp. 160. Date of Electronic Publication: 2024 Sep 16.

PROPERTY: PRESCRIPTIVE EASEMENTS AND A CHANGE FROM PERMISSIVE TO HOSTILE USE -- BOLDT V. ROTH.

Autor: Chelstrom, Jeffrey

Publikováno v: William Mitchell Law Review; 2002, Vol. 28 Issue 3, p1283-1306, 24p